Sažetak
Background: Hepatic and renal dysfunction, immune imbalance, and excessive inflammatory activation are common complications in postoperative infections. This study evaluated the biochemical effects of personalized clinical interventions on hepatorenal function, immune responses, and inflammatory cytokines in infected patients.
Methods: A total of 110 patients with postoperative infections admitted between January 2023 and January 2025 were randomly assigned to an experimental group or a control group (n = 55 each). The control group received standard clinical care, while the experimental group underwent additional individualized intervention measures. Serum hepatic (AST, ALT) and renal (BUN, SCr, UA) biochemical markers, T-lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺), inflammatory factors (IL-6, CRP, TNF-α), and SF-36 quality-of-life scores were assessed before and after intervention. Adverse events were recorded.
Results: Post-intervention, AST and ALT levels were significantly lower in the experimental group compared with the control group (P < 0.05). BUN, SCr, and UA were also significantly reduced after individualized intervention (P < 0.05). The experimental group demonstrated higher CD3⁺ and CD4⁺ levels and lower CD8⁺ levels than the control group (P < 0.05). Levels of IL-6, CRP, and TNF-α were markedly decreased in the experimental group (P < 0.05). Quality-of-life scores across all domains were significantly higher following individualized intervention (P < 0.05). The incidence of adverse reactions was notably lower in the experimental group (5.45% vs. 20.00%; χ² = 4.010, P = 0.045).
Conclusion: Personalized clinical interventions significantly improved hepatic and renal biochemical indices, enhanced immune function, and reduced systemic inflammatory cytokines in patients with postoperative infections. These findings support the integration of individualized strategies into infection management to optimize biochemical and clinical outcomes.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.